Herceptin Sales Data
| Rank 25 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Herceptin U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 25 ( 1) |
$473,632 | 1.53% | 167 | 3.09% |
| Q3 2013 | 24 ( 2) |
$466,498 | -0.30% | 162 | -2.41% |
| Q2 2013 | 26 (2) |
$467,892 | -0.74% | 166 | -0.60% |
| Q1 2013 | 24 | $471,387 | 1.43% | 167 | 1.83% |
| Q4 2012 | 24 (2) |
$464,737 | 3.22% | 164 | 1.23% |
| Q3 2012 | 26 (4) |
$450,251 | -0.84% | 162 | -0.61% |
| Q2 2012 | 30 (3) |
$454,063 | 6.67% | 163 | 5.16% |
| Q1 2012 | 33 | $425,687 | -0.06% | 155 | n/a |
| Q4 2011 | 33 (2) |
$425,931 | 7.61% | 155 | 4.73% |
| Q3 2011 | 31 (1) |
$395,804 | -0.64% | 148 | -0.67% |
| Q2 2011 | 32 (4) |
$398,348 | 3.62% | 149 | 1.36% |
| Q1 2011 | 36 | $384,428 | n/a | 147 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.